% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • terry_amln terry_amln Mar 15, 2013 9:30 AM Flag

    Genomic Health Presents Twenty Two International Studies Demonstrating Worldwide Adoption and Value of Oncotype DX(R) Breast Cancer Test

    New Findings Emphasize Oncotype DX's Real-life Impact for Patients and Physicians and Reduction in Healthcare Costs, Underscore Value of Broader Access for All Patients
    Results Reinforce Oncotype DX as the Only Genomic Test to Guide Chemotherapy Decisions
    Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of results from 22 studies at the 13th St. Gallen International Breast Cancer Conference highlighting the impact of the Oncotype DX® breast cancer test around the world. New data continue to demonstrate the test's ability to change treatment decisions and provide economic value across multiple health care systems, while reinforcing its clinical validation, accuracy and precision. This unparalleled number of studies and consistency of results emphasize the benefit that the Oncotype DX test provides in breast cancer as the only genomic test shown to predict chemotherapy benefit.

    "Our extensive, unsurpassed body of clinical evidence showcases Oncotype DX's unique ability to play a critical role in breast cancer treatment, while providing a positive impact on health systems worldwide, at this time when societies are seeking value from their healthcare spending," said Steven Shak, M.D., chief medical officer and executive vice president of research and development, Genomic Health. "The volume of the high quality research presented at this major international breast cancer conference reflects our leadership in utilizing genomics to personalize breast cancer treatment and Oncotype DX's unique ability to accurately assess whether ER positive breast cancer patients will benefit from chemotherapy."
    Multiple Studies Continue to Reinforce Oncotype DX Test is the Only Genomic Test to Predict Chemotherapy Benefit
    The Oncotype DX Recurrence Score was developed to answer the specific question of which estrogen receptor positive breast cancer patients - representing 75 percent of all breast cancer diagnoses - need chemotherapy in addition to hormonal thera

29.66-0.07(-0.24%)Oct 21 4:00 PMEDT